These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37651992)

  • 21. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.
    Smit EF
    Future Oncol; 2024; 20(27):1961-1971. PubMed ID: 39012221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    Rogawski D; Cao T; Ma Q; Roy-O'Reilly M; Yao L; Xu N; Nagpal S
    J Neurooncol; 2024 Oct; 170(1):209-217. PubMed ID: 39073687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
    Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ
    Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
    Kang C
    Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab deruxtecan in breast cancer.
    Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
    Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
    Shitara K
    Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
    Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
    Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
    Ishii T; Shitara K
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan.
    Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H
    Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Sakamoto Y; Nishina T; Inaki K; Kuwahara Y; Wada N; Suto F; Arita T; Sugihara M; Tsuchihashi Z; Saito K; Kojima A; Yamaguchi K
    Nat Med; 2024 Jul; 30(7):1933-1942. PubMed ID: 38745009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
    Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
    Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
    Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-DXd: New Standard for HER2-Low Breast Cancer.
    Cancer Discov; 2022 Aug; 12(8):1828. PubMed ID: 35666611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
    J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.